| 0.253 0.023 (10.05%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.13 | 1-year : | 3.3 |
| Resists | First : | 1.82 | Second : | 2.82 |
| Pivot price | 0.54  |
|||
| Supports | First : | 0.2 | Second : | 0.17 |
| MAs | MA(5) : | 0.23 |
MA(20) : | 0.69 |
| MA(100) : | 0.93 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 1.1 |
D(3) : | 1 |
| RSI | RSI(14): 37.8 |
|||
| 52-week | High : | 33.65 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LIMN ] has closed above bottom band by 35.7%. Bollinger Bands are 181.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.25 - 0.25 | 0.25 - 0.25 |
| Low: | 0.22 - 0.22 | 0.22 - 0.22 |
| Close: | 0.23 - 0.23 | 0.23 - 0.23 |
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
Wed, 18 Feb 2026
Liminatus Pharma Completes $4 Million Public Equity Offering - TipRanks
Tue, 17 Feb 2026
Liminatus Pharma prices $4 million public offering at $0.29 per share - Investing.com Canada
Thu, 12 Feb 2026
LIMN Liminatus Pharma (NASDAQ) pre-market +15% Feb 12 2026: earnings preview - Meyka
Tue, 10 Feb 2026
Why Credo Technology Group Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Tue, 10 Feb 2026
LIMN down 26.83% intraday: Liminatus Pharma (NASDAQ) 09 Feb 2026 earnings ahead - Meyka
Mon, 09 Feb 2026
Liminatus Pharma Settles Litigation Through Equity Issuance - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 31 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 43.9 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 60 (K) |
| Shares Short P.Month | 116 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -1.59 |
| PEG Ratio | 0 |
| Price to Book value | -4.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|